United Therapeutics Corporation
UTHR
株式のランク
#1030
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
株価
$533.18
最終同期: 2026-10-16
時価総額
$22.87B
変化（1日）
-1.54%
変化（1年）
23.04%
国
US
取引 United Therapeutics Corporation (UTHR)
カテゴリー
Healthcare
United Therapeutics Corporation（UTHR）の営業利益率
October 2026 時点の営業利益率 TTM: 44.49%
United Therapeutics Corporation の最新の財務報告と株価によると、現在の営業利益率（TTM）は 44.49% です。2023 年末時点では 50.91% でした。
United Therapeutics Corporation の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 44.49% | -7.04% |
| 2024 | 47.86% | -5.99% |
| 2023 | 50.91% | 0.61% |
| 2022 | 50.60% | 53.43% |
| 2021 | 32.98% | -17.59% |
| 2020 | 40.02% | -409.03% |
| 2019 | -12.95% | -126.17% |
| 2018 | 49.48% | 4.76% |
| 2017 | 47.23% | -28.88% |
| 2016 | 66.41% | 39.25% |
| 2015 | 47.69% | 14.04% |
| 2014 | 41.82% | 59.68% |
| 2013 | 26.19% | -43.10% |
| 2012 | 46.03% | 7.65% |
| 2011 | 42.76% | 57.44% |
| 2010 | 27.16% | 286.34% |
| 2009 | 7.03% | -124.12% |
| 2008 | -29.15% | -1,074.92% |
| 2007 | 2.99% | -83.54% |
| 2006 | 18.16% | -50.92% |
| 2005 | 37.00% | 106.13% |
| 2004 | 17.95% | -183.06% |
| 2003 | -21.61% | -63.84% |
| 2002 | -59.77% | -92.70% |
| 2001 | -818.93% | -79.41% |
| 2000 | -3,977.08% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -99.13% |
US
|
|
| -149.01% | -103.35% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.35% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。